Pharmaceuticals

10 pharma consultants

These ten pharma consultants advise pharmaceutical and biotech companies, and nine of them lead consulting practices as founders, presidents or CEOs. A reader can learn how to plan a launch, build a market access and pricing strategy, and prepare commercial teams for a new medicine.

10 professionals10 companiesData retrieved September 29, 2026

Professionals to explore

01—10
  1. Asif Velani

    LinkedIn

    Experience: Founder · Aperture Biopharma Consulting

    Founder of Aperture Biopharma Consulting since 2017. Former Head of Market Access at Puma Biotechnology, Inc. (2017), Senior Expert, Pharmaceutical and Medical Products at McKinsey & Company (2015–2016) and Director, Strategic Pricing & Contracting at Genentech (2011–2014). His profile describes him as a market access leader with experience as an expert, implementor and clinician.

  2. Bernd Schollmeier

    LinkedIn

    Experience: Founder & Managing Director · Helvetic Consulting GmbH

    Founder & Managing Director of Helvetic Consulting GmbH since 2025. Former External Partner Global Pharma (2025) and Vice President of Global Market Access Vaccines (2021–2024) at Alira Health, and former Freelance Consultant for Global Market Access (2020–2021). His profile says he helps biopharma and vaccine innovators turn scientific innovation into reimbursed global success by aligning market access, pricing and evidence.

  3. Betsy J. Lahue

    LinkedIn

    Experience: CEO - HEOR & Market Access Consulting For Pharmaceutical & Life Sciences Companies · Alkemi

    CEO - HEOR & Market Access Consulting For Pharmaceutical & Life Sciences Companies at Alkemi since 2017. Former Worldwide Vice President, Corporate Strategic Marketing, Global Leader HEOR and Market Access at BD (2010–2016). Her profile says Alkemi helps pharmaceutical, biotech and medtech leaders prove value, build evidence and improve patient access to treatments.

  4. Bob Marchesani

    LinkedIn

    Experience: President and Principal Consultant · Proventus Consulting LLC

    President and Principal Consultant at Proventus Consulting LLC since 2017, and former holder of senior global commercial leadership roles in oncology at Eli Lilly and Company (1990–2017). His profile says he advises biotech and pharmaceutical CEOs and executive teams, primarily in oncology, on enterprise commercial strategy, launch readiness and value creation across the asset lifecycle.

  5. Eileen McCormack

    LinkedIn

    Experience: Pharmaceutical Consultant · Perspective Consulting

    Pharmaceutical Consultant at Perspective Consulting since 2018. Former Head, New Product Planning and Business Development (2014–2017) and Director New Products and Business Development (2010–2014) at AstraZeneca. Her profile describes commercial experience across product and portfolio strategy and execution at global and local levels in the US, Canada and Japan, and lists CEO consultant and interim CEO positions.

  6. Guadalupe Viveros

    LinkedIn

    Experience: Founder & Managing Director · Kovaris Health Strategy

    Founder & Managing Director of Kovaris Health Strategy since 2026, and former Principal Consultant at Adivo, a Herspiegel company (2016–2024) and Consultant at IQVIA (2014–2016). Her profile describes her as a pharma and healthcare strategy consultant advising pharma, biotech and healthcare companies across LATAM, EU5 and the US on launches, market entry, competitive intelligence and patient journey mapping.

  7. Laura Viaches

    LinkedIn

    Experience: President & Principal Consultant · Endeavor Pharma Solutions

    President & Principal Consultant at Endeavor Pharma Solutions since 2025. Former Associate Vice President, Market Access-Alzheimer's Disease (2021–2024), Associate Vice President, Patient Services (2017–2021) and Senior Director, Payer Strategy (2013–2015) at Eli Lilly and Company. Her profile describes her practice as market access consulting for companies navigating commercialization.

  8. Olga Tikhonova

    LinkedIn

    Experience: Director Founder · Insights4Pharma

    Director Founder of Insights4Pharma since 2011; her profile describes her as a strategy consultant helping pharmaceutical companies launch and commercialise their products, focusing on commercial and market access strategies, competitive mitigation and new product launches. Former Senior European Brand Manager - Endocrine Care at Pfizer (2008–2011) and Senior Product Manager - Multiple Sclerosis at Bayer (2006–2007).

  9. Paula Keebler

    LinkedIn

    Experience: Founder & Principal, Biopharma Commercial & Strategy Consulting Practice · Paula Keebler Advisory

    Founder & Principal, Biopharma Commercial & Strategy Consulting Practice at Paula Keebler Advisory since 2018. Her listing shows a Mirum Pharmaceuticals role described as Consultant (2020–2022, via the advisory practice) and Executive Director, Global Product Strategy (2025). Her profile highlights product strategy, launch readiness and commercialization, with a rare disease and oncology focus.

  10. Robert Paglia, RPh, MBA

    LinkedIn

    Experience: President · Market Access Consulting LLC

    President of Market Access Consulting LLC since 2026, an independent firm his profile says provides strategic consulting for the biopharmaceutical industry. Former Vice President, Market Access at Servier Pharmaceuticals (2019–2026), Managing Director, Pricing and Market Access at Consulting at McCann Health (2017–2018) and US Head, Pricing and Market Access Consulting at ICON plc (2015–2016).

Choose the right perspective

Match the consultant's specialty to your question: market access, pricing and HEOR specialists suit payer and reimbursement planning, while commercial strategy and launch advisors suit brand planning and go-to-market decisions. Ask which therapeutic areas and countries they have worked in, since access rules differ widely by market.

Questions to take into the conversation

  1. 01What evidence do payers need to see before launch to grant favorable access for a new medicine?
  2. 02How early should a pharma company start launch planning, and what should be in place well before approval?
  3. 03How do you set a launch price that works across the US and European markets?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Request a correction or removal

Other perspectives in Pharmaceuticals